About This Treatment

Myeloma Clinical Trials

A Phase 1/2a Study Investigating TAK-079 Administered Subcutaneously in Patients With Relapsed/Refractory Multiple Myeloma

This is a phase 1/2a study evaluating the safety, tolerability and the most appropriate dose, of TAK-079 monotherapy as treatment for patients with Relapsed/Refractory Multiple Myeloma.

Learn more about this trial

Treatment Information
Developed By

Takeda Oncology

Treatment Classifications

Create Your Account

Create your account today and get matched to myeloma treatments and trials around the US.

  • Find treatments with eligible clinical trials.
  • Get a second opinion from a myeloma specialist.
  • Receive alerts when new treatments become available.
  • Our services are always free for patients and HIPAA compliant.

Create Account

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST